{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:19:23Z","timestamp":1787915963817,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The legal funder of the study was the Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-026-01632-0","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:55:48Z","timestamp":1787914548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5914-504X","authenticated-orcid":false,"given":"Masahiro","family":"Hatori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-2841","authenticated-orcid":false,"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoka","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Arafune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-128X","authenticated-orcid":false,"given":"Takashi","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2023-1300","authenticated-orcid":false,"given":"Kazuyoshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9517-7283","authenticated-orcid":false,"given":"Wataru","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0831-0850","authenticated-orcid":false,"given":"Naoki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0672-7214","authenticated-orcid":false,"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-1970","authenticated-orcid":false,"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8667-9365","authenticated-orcid":false,"given":"Tomonobu","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-0529","authenticated-orcid":false,"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"10","key":"1632_CR1","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, Le Rhun E, Preusser M, Scott\u00e9 F, Taphoorn MJB, Jordan K (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 31(10):1306\u20131319. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.003","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"27\u201328","key":"1632_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3238\/arztebl.2017.0481","volume":"114","author":"K Jordan","year":"2017","unstructured":"Jordan K, Feyer P, H\u00f6ller U, Link H, W\u00f6rmann B, Jahn F (2017) Supportive treatments for patients with cancer. Dtsch Arztebl Int 114(27\u201328):481\u2013487. https:\/\/doi.org\/10.3238\/arztebl.2017.0481","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"1632_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1312","volume":"9","author":"A Molassiotis","year":"2019","unstructured":"Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, Ng TR, Suen LKP, Chan CW, Yorke J, Lopez V (2019) Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 9(6):e01312. https:\/\/doi.org\/10.1002\/brb3.1312","journal-title":"Brain Behav"},{"issue":"1\u20132","key":"1632_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jns.2014.12.041","volume":"349","author":"C Johnson","year":"2015","unstructured":"Johnson C, Pankratz VS, Velazquez AI, Aakre JA, Loprinzi CL, Staff NP, Windebank AJ, Yang P (2015) Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci 349(1\u20132):124\u2013128. https:\/\/doi.org\/10.1016\/j.jns.2014.12.041","journal-title":"J Neurol Sci"},{"issue":"24","key":"1632_CR5","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djp413","volume":"101","author":"M Bryd\u00f8y","year":"2009","unstructured":"Bryd\u00f8y M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O, Foss\u00e5 SD (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101(24):1682\u20131695. https:\/\/doi.org\/10.1093\/jnci\/djp413","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1632_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrneurol.2017.88","volume":"13","author":"AA Argyriou","year":"2017","unstructured":"Argyriou AA, Bruna J, Genazzani AA, Cavaletti G (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol 13(8):492\u2013504. https:\/\/doi.org\/10.1038\/nrneurol.2017.88","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1632_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/0284186x.2017.1415462","volume":"57","author":"MJ Iba\u00f1ez-Juli\u00e1","year":"2018","unstructured":"Iba\u00f1ez-Juli\u00e1 MJ, Berzero G, Reyes-Botero G, Maisonobe T, Lenglet T, Slim M, Louis S, Balaguer A, Sanson M, Le Guern E, Latour P, Ricard D, Stojkovic T, Psimaras D (2018) Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. Acta Oncologica (Stockholm, Sweden) 57(3):403\u2013411. https:\/\/doi.org\/10.1080\/0284186x.2017.1415462","journal-title":"Acta Oncologica (Stockholm, Sweden)"},{"issue":"25","key":"1632_CR8","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/jco.2015.66.2346","volume":"34","author":"DL Hershman","year":"2016","unstructured":"Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. J Clin Oncol 34(25):3014\u20133022. https:\/\/doi.org\/10.1200\/jco.2015.66.2346","journal-title":"J Clin Oncol"},{"issue":"13","key":"1632_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359\u20131367. https:\/\/doi.org\/10.1001\/jama.2013.2813","journal-title":"JAMA"},{"issue":"11","key":"1632_CR10","doi-asserted-by":"publisher","first-page":"e1024","DOI":"10.1634\/theoncologist.2017-0664","volume":"24","author":"E Ciruelos","year":"2019","unstructured":"Ciruelos E, Apell\u00e1niz-Ruiz M, Cantos B, Martinez-J\u00e1\u00f1ez N, Bueno-Mui\u00f1o C, Echarri MJ, Enrech S, Guerra JA, Manso L, Pascual T, Dominguez C, Gonzalo JF, Sanz JL, Rodriguez-Antona C, Sep\u00falveda JM (2019) A pilot, phase II, randomized, open-label clinical trial comparing the neurotoxicity of three dose regimens of nab-paclitaxel to that of solvent-based paclitaxel as the first-line treatment for patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer. Oncologist 24(11):e1024\u2013e1033. https:\/\/doi.org\/10.1634\/theoncologist.2017-0664","journal-title":"Oncologist"},{"issue":"4","key":"1632_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/s0009-9236(03)00228-5","volume":"74","author":"M Niemi","year":"2003","unstructured":"Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ (2003) Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74(4):380\u2013387. https:\/\/doi.org\/10.1016\/s0009-9236(03)00228-5","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1632_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383\u2013391. https:\/\/doi.org\/10.1038\/86882","journal-title":"Nat Genet"},{"issue":"1","key":"1632_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/sj.clpt.6100011","volume":"81","author":"NF Smith","year":"2007","unstructured":"Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A (2007) Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 81(1):76\u201382. https:\/\/doi.org\/10.1038\/sj.clpt.6100011","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"1632_CR14","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.ejca.2006.06.017","volume":"42","author":"TM Sissung","year":"2006","unstructured":"Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer (Oxford, England\u202f: 1990) 42(17):2893\u20132896. https:\/\/doi.org\/10.1016\/j.ejca.2006.06.017","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"29","key":"1632_CR15","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1200\/jco.2006.10.4752","volume":"25","author":"S Marsh","year":"2007","unstructured":"Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(29):4528\u20134535. https:\/\/doi.org\/10.1200\/jco.2006.10.4752","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"1632_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/bjc.2016.326","volume":"115","author":"SW Lam","year":"2016","unstructured":"Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E (2016) Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. Br J Cancer 115(11):1335\u20131342. https:\/\/doi.org\/10.1038\/bjc.2016.326","journal-title":"Br J Cancer"},{"key":"1632_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygyno.2024.04.021","volume":"187","author":"M Zenatri","year":"2024","unstructured":"Zenatri M, Perennec T, Michon C, Gernier F, Grellard JM, Piloquet FX, Dubot-Poitelon C, Kalbacher E, Tredan O, Augereau P, Pautier P, Fey L, Joly F, Frenel JS (2024) Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: a substudy of the GINECO Vivrovaire study. Gynecol Oncol 187:139\u2013144. https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1632_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-024-00325-2","volume":"24","author":"M Liu","year":"2024","unstructured":"Liu M, Hernandez S, Aquilante CL, Deininger KM, Lindenfeld J, Schlendorf KH, Van Driest SL (2024) Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients. Pharmacogenomics J 24(2):4. https:\/\/doi.org\/10.1038\/s41397-024-00325-2","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"1632_CR19","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1111\/cts.13370","volume":"15","author":"A Guijosa","year":"2022","unstructured":"Guijosa A, Freyria A, Espinosa-Fernandez JR, Estrada-Mena FJ, Armenta-Quiroga AS, Ortega-Trevi\u00f1o MF, Catal\u00e1n R, Antonio-Aguirre B, Villarreal-Garza C, Perez-Ortiz AC (2022) Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: systematic review and meta-analysis. Clin Transl Sci 15(10):2403\u20132436. https:\/\/doi.org\/10.1111\/cts.13370","journal-title":"Clin Transl Sci"},{"issue":"17","key":"1632_CR20","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1002\/cncr.35343","volume":"130","author":"M Hatori","year":"2024","unstructured":"Hatori M, Tsuji D, Suzuki K, Yokokawa T, Kawakami K, Moriyama R, Osada-Tsuchiya M, Otake A, Nakao M, Yano T, Arakawa Y, Matsuo K, Ohashi Y, Sakata Y, Kogure Y, Tamaki S, Wada A, Taki Y, Sasahira N, Ishii H, Yamaguchi M, Itoh K (2024) Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: a multicenter, prospective, observational cohort study (GENESECT study). Cancer 130(17):2988\u20132999. https:\/\/doi.org\/10.1002\/cncr.35343","journal-title":"Cancer"},{"issue":"1","key":"1632_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser 57(1):289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x","journal-title":"J Roy Statist Soc Ser"},{"issue":"12","key":"1632_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261473","volume":"16","author":"S Hiramoto","year":"2021","unstructured":"Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A (2021) Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: a retrospective study in Japan. PLoS ONE 16(12):e0261473. https:\/\/doi.org\/10.1371\/journal.pone.0261473","journal-title":"PLoS ONE"},{"issue":"12","key":"1632_CR23","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.21873\/anticanres.16764","volume":"43","author":"A Kobayashi","year":"2023","unstructured":"Kobayashi A, Ikemura K, Wakai E, Kondo M, Okuda M (2023) Proton pump inhibitors ameliorate oxaliplatin-induced peripheral neuropathy: retrospective analysis of two real-world clinical databases. Anticancer Res 43(12):5613\u20135620. https:\/\/doi.org\/10.21873\/anticanres.16764","journal-title":"Anticancer Res"},{"issue":"4","key":"1632_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jamaoncol.2025.0001","volume":"11","author":"LL Michel","year":"2025","unstructured":"Michel LL, Schwarz D, Romar P, Feisst M, Hamberger D, Priester A, Kurre E, Klein E, M\u00fcller J, Schink\u00f6the T, Weiler M, Smetanay K, Fremd C, Heublein S, Thewes V, Breckwoldt MO, J\u00e4ger D, Bendszus M, Marm\u00e9 F, Schneeweiss A (2025) Efficacy of hand cooling and compression in preventing taxane-induced neuropathy: the POLAR randomized clinical trial. JAMA Oncol 11(4):408\u2013415. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0001","journal-title":"JAMA Oncol"},{"issue":"1","key":"1632_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/jto.0000000000000011","volume":"9","author":"V Hirsh","year":"2014","unstructured":"Hirsh V, Okamoto I, Hon JK, Page RD, Orsini J, Sakai H, Zhang H, Renschler MF, Socinski MA (2014) Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 9(1):83\u201390. https:\/\/doi.org\/10.1097\/jto.0000000000000011","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"10046","key":"1632_CR26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/s0140-6736(16)30175-1","volume":"388","author":"BMIMC Global","year":"2016","unstructured":"Global BMIMC, Di Angelantonio E, Bhupathiraju ShN, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns BJ, Huxley R, Jackson ChL, Joshy G, Lewington S, Manson JE, Murphy N, Patel AV, Samet JM, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR, Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda RJ, McLerran DF, Moore SC, O\u2019Keeffe LM, Paige E, Ramond A, Reeves GK, Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun YD, Willeit P, Banks E, Beral V, Chen Z, Gapstur SM, Gunter MJ, Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG, Danesh J, Hu FB (2016) Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (London, England) 388(10046):776\u2013786. https:\/\/doi.org\/10.1016\/s0140-6736(16)30175-1","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1632_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","volume":"82","author":"AA Argyriou","year":"2012","unstructured":"Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51\u201377. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.04.012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"1632_CR28","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/0008-5472.Can-20-2799","volume":"81","author":"M Koyanagi","year":"2021","unstructured":"Koyanagi M, Imai S, Matsumoto M, Iguma Y, Kawaguchi-Sakita N, Kotake T, Iwamitsu Y, Ntogwa M, Hiraiwa R, Nagayasu K, Saigo M, Ogihara T, Yonezawa A, Omura T, Nakagawa S, Nakagawa T, Matsubara K (2021) Pronociceptive roles of schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy. Cancer Res 81(8):2207\u20132219. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-2799","journal-title":"Cancer Res"},{"issue":"4","key":"1632_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/08916934.2021.1919881","volume":"54","author":"EGC Cunha","year":"2021","unstructured":"Cunha EGC, de Lima CAD, Vilar KM, N\u00f3brega MF, Almeida AR, Pereira MC, Dantas AT, Gon\u00e7alves RSG, R\u00eago M, Duarte A, Pitta M (2021) Genetic variants in LGALS3 are related to lower galectin-3 serum levels and clinical outcomes in systemic sclerosis patients: a case-control study. Autoimmunity 54(4):187\u2013194. https:\/\/doi.org\/10.1080\/08916934.2021.1919881","journal-title":"Autoimmunity"},{"issue":"6","key":"1632_CR30","doi-asserted-by":"publisher","first-page":"8144","DOI":"10.3892\/ol.2017.7258","volume":"14","author":"Y Shi","year":"2017","unstructured":"Shi Y, Lin X, Chen G, Yan J, Ying M, Zheng X (2017) Galectin-3 rs4652 A>C polymorphism is associated with the risk of gastric carcinoma and P-glycoprotein expression level. Oncol Lett 14(6):8144\u20138149. https:\/\/doi.org\/10.3892\/ol.2017.7258","journal-title":"Oncol Lett"},{"issue":"7","key":"1632_CR31","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1089\/thy.2020.0366","volume":"31","author":"A Corrado","year":"2021","unstructured":"Corrado A, Aceto R, Silvestri R, Dell\u2019Anno I, Ricci B, Miglietta S, Romei C, Giovannoni R, Poliseno L, Evangelista M, Vitiello M, Cipollini M, Garritano S, Giusti L, Zallocco L, Elisei R, Landi S, Gemignani F (2021) Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR\/Cas9 system. Thyroid Off J Am Thyroid Assoc 31(7):1056\u20131066. https:\/\/doi.org\/10.1089\/thy.2020.0366","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"issue":"11","key":"1632_CR32","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/ijc.25254","volume":"127","author":"P Nangia-Makker","year":"2010","unstructured":"Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A (2010) Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 127(11):2530\u20132541. https:\/\/doi.org\/10.1002\/ijc.25254","journal-title":"Int J Cancer"},{"issue":"24","key":"1632_CR33","doi-asserted-by":"publisher","first-page":"10045","DOI":"10.1158\/0008-5472.Can-08-3224","volume":"68","author":"V Balan","year":"2008","unstructured":"Balan V, Nangia-Makker P, Schwartz AG, Jung YS, Tait L, Hogan V, Raz T, Wang Y, Yang ZQ, Wu GS, Guo Y, Li H, Abrams J, Couch FJ, Lingle WL, Lloyd RV, Ethier SP, Tainsky MA, Raz A (2008) Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res 68(24):10045\u201310050. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-3224","journal-title":"Cancer Res"},{"issue":"3","key":"1632_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13402-012-0075-7","volume":"35","author":"F Wu","year":"2012","unstructured":"Wu F, Hu N, Li Y, Bian B, Xu G, Zheng Y (2012) Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cell Oncol (Dordrecht, Netherlands) 35(3):175\u2013180. https:\/\/doi.org\/10.1007\/s13402-012-0075-7","journal-title":"Cell Oncol (Dordrecht, Netherlands)"},{"issue":"9","key":"1632_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1159\/000475502","volume":"40","author":"SQ Fang","year":"2017","unstructured":"Fang SQ, Feng YM, Li M (2017) Correlations of Galectin-3 gene polymorphisms with risk and prognosis of cervical cancer in Chinese populations: a case-control study. Oncol Res Treat 40(9):533\u2013539. https:\/\/doi.org\/10.1159\/000475502","journal-title":"Oncol Res Treat"},{"issue":"1","key":"1632_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.urolonc.2010.09.011","volume":"31","author":"A Meyer","year":"2013","unstructured":"Meyer A, Coinac I, Bogdanova N, Dubrowinskaja N, Turmanov N, Haubold S, Sch\u00fcrmann P, Imkamp F, von Klot C, Merseburger AS, Machtens S, Bremer M, Hillemanns P, Kuczyk MA, Karstens JH, Serth J, D\u00f6rk T (2013) Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Urol Oncol 31(1):74\u201381. https:\/\/doi.org\/10.1016\/j.urolonc.2010.09.011","journal-title":"Urol Oncol"},{"issue":"2","key":"1632_CR37","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s11033-021-06150-1","volume":"48","author":"R Saez-Maleta","year":"2021","unstructured":"Saez-Maleta R, Merino-Merino A, Gundin-Menendez S, Salgado-Aranda R, AlKassam-Martinez D, Pascual-Tejerina V, Martin-Gonzalez J, Garcia-Fernandez J, Perez-Rivera JA (2021) sST2 and Galectin-3 genotyping in patients with persistent atrial fibrillation. Mol Biol Rep 48(2):1601\u20131606. https:\/\/doi.org\/10.1007\/s11033-021-06150-1","journal-title":"Mol Biol Rep"},{"issue":"9","key":"1632_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1370","volume":"8","author":"YH Liao","year":"2020","unstructured":"Liao YH, Teng MS, Juang JJ, Chiang FT, Er LK, Wu S, Ko YL (2020) Genetic determinants of circulating galectin-3 levels in patients with coronary artery disease. Mol Genet Genomic Med 8(9):e1370. https:\/\/doi.org\/10.1002\/mgg3.1370","journal-title":"Mol Genet Genomic Med"},{"key":"1632_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.gene.2017.11.026","volume":"642","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wang Y, Zhai M, Gan T, Zhao X, Zhang R, An T, Huang Y, Zhou Q, Zhang J (2018) Influence of LGALS3 gene polymorphisms on susceptibility and prognosis of dilated cardiomyopathy in a Northern Han Chinese population. Gene 642:293\u2013298. https:\/\/doi.org\/10.1016\/j.gene.2017.11.026","journal-title":"Gene"},{"issue":"9","key":"1632_CR40","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s10067-011-1741-2","volume":"30","author":"CY Hu","year":"2011","unstructured":"Hu CY, Chang SK, Wu CS, Tsai WI, Hsu PN (2011) Galectin-3 gene (LGALS3) +292C allele is a genetic predisposition factor for rheumatoid arthritis in Taiwan. Clin Rheumatol 30(9):1227\u20131233. https:\/\/doi.org\/10.1007\/s10067-011-1741-2","journal-title":"Clin Rheumatol"},{"key":"1632_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104419","volume":"368","author":"WD Xu","year":"2021","unstructured":"Xu WD, Wu Q, He YW, Huang AF, Lan YY, Fu L, Zhou J, Liu XY (2021) Gene polymorphisms of LGALS2, LGALS3 and LGALS9 in patients with rheumatoid arthritis. Cell Immunol 368:104419. https:\/\/doi.org\/10.1016\/j.cellimm.2021.104419","journal-title":"Cell Immunol"},{"issue":"4","key":"1632_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5937\/jomb0-30424","volume":"40","author":"BA Ibrahim","year":"2021","unstructured":"Ibrahim BA, Mohamed SH, Hassaan MMM, Sabbah NA (2021) Associations of galectin-3 expression and LGALS-3 (rs4652) gene variant with coronary artery disease risk in diabetics. J Med Biochem 40(4):395\u2013406. https:\/\/doi.org\/10.5937\/jomb0-30424","journal-title":"J Med Biochem"},{"issue":"11","key":"1632_CR43","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2217\/bmm-2020-0269","volume":"14","author":"H Fu","year":"2020","unstructured":"Fu H, Nie S, Luo P, Ruan Y, Zhang Z, Miao H, Li X, Wen S, Bai R (2020) Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes. Biomark Med 14(11):943\u2013954. https:\/\/doi.org\/10.2217\/bmm-2020-0269","journal-title":"Biomark Med"},{"issue":"2","key":"1632_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5606\/tgkdc.dergisi.2021.20141","volume":"29","author":"\u015e Terzio\u011flu-U\u015fak","year":"2021","unstructured":"Terzio\u011flu-U\u015fak \u015e, Horozo\u011flu C, Demirkol \u015e, Turna A, Yayl\u0131m \u0130 (2021) The role of galectin-3 and its genetic variants in tumor risk and survival of patients with surgically resected early-stage non-small cell lung cancer. Turk Gogus Kalp Damar Cerrahisi Derg 29(2):212\u2013222. https:\/\/doi.org\/10.5606\/tgkdc.dergisi.2021.20141","journal-title":"Turk Gogus Kalp Damar Cerrahisi Derg"},{"key":"1632_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-34830-6","author":"O Tarasiuk","year":"2026","unstructured":"Tarasiuk O, Chiorazzi A, Argentini A, Ballarini E, Canta A, Carozzi VA, Pozzi E, Alberti P, Fabbro V, Iseppon F, Foti M, Meregalli C (2026) Interleukin-6 as a keystone cytokine in experimental rat models of chemotherapy-induced peripheral neurotoxicity. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-025-34830-6","journal-title":"Sci Rep"},{"issue":"10","key":"1632_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047385","volume":"7","author":"RA de Boer","year":"2012","unstructured":"de Boer RA, Verweij N, van Veldhuisen DJ, Westra HJ, Bakker SJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Franke L, Mateo Leach I, van der Harst P (2012) A genome-wide association study of circulating galectin-3. PLoS ONE 7(10):e47385. https:\/\/doi.org\/10.1371\/journal.pone.0047385","journal-title":"PLoS ONE"},{"issue":"1","key":"1632_CR47","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12967-022-03754-4","volume":"20","author":"K Hooshmand","year":"2022","unstructured":"Hooshmand K, Goldstein D, Timmins HC, Li T, Harrison M, Friedlander ML, Lewis CR, Lees JG, Moalem-Taylor G, Guennewig B, Park SB, Kwok JB (2022) Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study. J Transl Med 20(1):564. https:\/\/doi.org\/10.1186\/s12967-022-03754-4","journal-title":"J Transl Med"},{"issue":"2","key":"1632_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1158\/1078-0432.Ccr-12-2618","volume":"19","author":"HE Wheeler","year":"2013","unstructured":"Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ, Dolan ME (2013) Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 19(2):491\u2013499. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-2618","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1632_CR49","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00520-025-09392-y","volume":"33","author":"MK Jones","year":"2025","unstructured":"Jones MK, Nicklawsky A, Shortt J, Pattee J, Kennerley V, Eule CJ, Candelario N, O\u2019Donnell PH, Flaig TW (2025) Pharmacogenomics of chemotherapy induced peripheral neuropathy using an electronic health record-derived definition: a genome-wide association study. Support Care Cancer 33(5):362. https:\/\/doi.org\/10.1007\/s00520-025-09392-y","journal-title":"Support Care Cancer"},{"issue":"1","key":"1632_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12974-019-1581-6","volume":"16","author":"M Tsubota","year":"2019","unstructured":"Tsubota M, Fukuda R, Hayashi Y, Miyazaki T, Ueda S, Yamashita R, Koike N, Sekiguchi F, Wake H, Wakatsuki S, Ujiie Y, Araki T, Nishibori M, Kawabata A (2019) Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin\/thrombomodulin system in rodents: negative impact of anticoagulants. J Neuroinflammation 16(1):199. https:\/\/doi.org\/10.1186\/s12974-019-1581-6","journal-title":"J Neuroinflammation"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01632-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01632-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01632-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:55:50Z","timestamp":1787914550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01632-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":50,"alternative-id":["1632"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01632-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol and informed consent forms were approved by the ethics committee of each facility. Informed consent was obtained from all subjects prior to participation in the study. This study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript has no any individual person\u2019s data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}